

On behalf of Bent Deleuran:

SEMINAR

Wednesday **September 23th 2015**, 12.00 to 15.00, Merete Barker Auditorium

PD-1 in cancer, implications for immunotherapy

PD-1 is a central placed co-stimulatory factor that plays an important role in keeping our immunological tolerance.

Recently anti-PD-1 and anti-PD-L1 antibodies have shown to be extremely potent treatments for various cancers.

MSD Denmark and Merck Research labs, Palo Alto, will host a seminar on the PD-1 axis.

Agenda.

12.00 - 13.00 Jennifer Yearley

DVM, PhD, DACVP, Senior Principal Scientist and anatomic Pathology Group Leader at Biologics Discovery, Merck Research Lab. Palo Alto, CA.

Understanding mechanisms of response vs. non-response to immunotherapy and the development of predictive biomarkers.

13.00 – 13.30 Lunch – Hosted by MSD Denmark

13.30 – 14.45 Elaine Pinheiro

PhD. Principal Scientist at in vivo Pharmacology – Oncology, Merck Research Lab. Boston, MA.

Preclinical strategies to support the clinical development of an anti-PD-1 antibody.

14.45 – 15.00 Discussion and closing remarks

How

Just show up or secure your seat and lunch by following this link: tilmelding.msddinfo.dk/b11436

See you at the Merete Barker Auditorium

Sincerely,

Stinna Bastian

MSD Denmark

stinna.bastian@merck.com

&

Bent Deleuran

Institute of Biomedicine, Aarhus University

bd@biomed.au.dk